Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamza Lodhi

Hospitalist Southaven, MS Medical Doctor

NPI 1346479235 CMS profile 487161

7601 Southcrest Parkway, Southaven, MS 38671

Open in the dashboard

General payments

$164,282

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hamza Lodhi of Southaven, MS is reported in the CMS Open Payments database as having received $164,282 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,375 46
2024 General $2,418 37
2023 General $154,842 12
2022 General $893 14
2021 General $517 11
2020 General $464 11
2019 General $774 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamza Lodhi
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Hamza Lodhi were reported at $4,375. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Hamza Lodhi Hospitalist median Middle half National median
2019 $774 $96 $28–$201 $163
2020 $464 $48 $19–$125 $114
2021 $517 $70 $23–$167 $132
2022 $893 $85 $27–$174 $149
2023 $154,842 $89 $30–$191 $160
2024 $2,418 $95 $29–$204 $164
2025 $4,375 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $100,664 12 payments
  2. Boston Scientific Corporation $50,935 24 payments
  3. Abbott Laboratories $7,626 32 payments
  4. Edwards Lifesciences Corporation $3,066 27 payments
  5. Abiomed $309 5 payments
  6. Shockwave Medical, Inc $276 3 payments
  7. Medtronic Vascular, Inc. $203 2 payments
  8. Cardiva Medical, Inc. $187 4 payments
  9. Astellas Pharma US Inc $150 3 payments
  10. Cardiac Dimensions, Inc. $133 1 payment
  11. Other $734 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $154,500 3 payments
  2. Food and Beverage $6,702 119 payments
  3. Travel and Lodging $2,830 13 payments
  4. Education $250 3 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $100,464 10 payments
  2. TRICLIP $1,406 10 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,216 13 payments
  4. SAPIEN 3 Ultra RESILIA $968 8 payments
  5. Mitra Clip system $678 8 payments
  6. MITRACLIP Vascular $372 3 payments
  7. Impella $309 5 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $300 3 payments
  9. MitraClip Structural Heart $272 2 payments
  10. WATCHMAN Access System $232 9 payments
  11. Other $2,936 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

158

Median for Interventional Cardiology: 2,236

Drug cost

$1,801

Median for Interventional Cardiology: $380,412

Branded share of claims

90.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 143 $1,774
Atorvastatin Calcium Generic 15 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$75,303

Medicare's payments for the services billed

Medicare patients

370

Average age 76

Services billed

947

190 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 54%
Heart failure 53%
Diabetes 51%
Atrial fibrillation 45%
Chronic kidney disease 45%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record